| EASL clinical practice guidelines: management of hepatocellular carcinoma PR Galle, A Forner, JM Llovet, V Mazzaferro, F Piscaglia, JL Raoul, ... Journal of hepatology 69 (1), 182-236, 2018 | 11615* | 2018 |
| Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 366 (9503), 2087-2106, 2005 | 6293 | 2005 |
| Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor F Ciardiello, R Caputo, R Bianco, V Damiano, G Pomatico, S De Placido, ... Clinical Cancer Research 6 (5), 2053-2063, 2000 | 1306 | 2000 |
| Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3 DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ... Journal of Clinical Oncology 36 (24), 2465-2472, 2018 | 1031 | 2018 |
| Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor F Ciardiello, R Caputo, R Bianco, V Damiano, G Fontanini, S Cuccato, ... Clinical cancer research 7 (5), 1459-1465, 2001 | 818 | 2001 |
| Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance G Arpino, H Weiss, AV Lee, R Schiff, S De Placido, CK Osborne, ... Journal of the National Cancer Institute 97 (17), 1254-1261, 2005 | 649 | 2005 |
| Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer G Di Lorenzo, G Tortora, FP D’Armiento, G De Rosa, S Staibano, ... Clinical cancer research 8 (11), 3438-3444, 2002 | 612 | 2002 |
| c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. C Carlomagno, F Perrone, C Gallo, M De Laurentiis, R Lauria, A Morabito, ... Journal of Clinical Oncology 14 (10), 2702-2708, 1996 | 575 | 1996 |
| Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials M De Laurentiis, G Cancello, D D'Agostino, M Giuliano, A Giordano, ... Journal of clinical oncology 26 (1), 44-53, 2008 | 555 | 2008 |
| Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense … F Ciardiello, R Bianco, V Damiano, G Fontanini, R Caputo, G Pomatico, ... Clinical Cancer Research 6 (9), 3739-3747, 2000 | 521 | 2000 |
| Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials M Di Maio, C Gallo, NB Leighl, MC Piccirillo, G Daniele, F Nuzzo, ... Journal of Clinical oncology 33 (8), 910-915, 2015 | 479 | 2015 |
| Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 F Ciardiello, R Bianco, V Damiano, S De Lorenzo, S Pepe, S De Placido, ... Clinical Cancer Research 5 (4), 909-916, 1999 | 436 | 1999 |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ... NPJ breast cancer 7 (1), 1, 2021 | 431 | 2021 |
| A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer M De Laurentiis, G Arpino, E Massarelli, A Ruggiero, C Carlomagno, ... Clinical cancer research 11 (13), 4741-4748, 2005 | 428 | 2005 |
| Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth … F Ciardiello, R Bianco, R Caputo, R Caputo, V Damiano, T Troiani, ... Clinical Cancer Research 10 (2), 784-793, 2004 | 425 | 2004 |
| Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial S Pignata, G Scambia, D Katsaros, C Gallo, E Pujade-Lauraine, ... The Lancet Oncology 15 (4), 396-405, 2014 | 423 | 2014 |
| Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study G Fontanini, S Vignati, F Basolo, G Bevilacqua, M Lucchi, A Mussi, ... Journal of the National Cancer Institute 89 (12), 881-886, 1997 | 408 | 1997 |
| Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin … G Fontanini, M De Laurentiis, S Vignati, S Chine, M Lucchi, V Silvestri, ... Clinical cancer research: an official journal of the American Association …, 1998 | 407 | 1998 |
| A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients F De Vita, M Orditura, E Matano, R Bianco, C Carlomagno, S Infusino, ... British journal of cancer 92 (9), 1644-1649, 2005 | 357 | 2005 |
| A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients Cancer of the Liver Italian Program (CLIP) Investigators Hepatology 28 (3), 751-755, 1998 | 356 | 1998 |
